ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences completed enrollment of 144 patients in its PRECISE-AD Phase 1b trial for Alzheimer’s disease, with positive safety results to date and anticipated interim data in Q3 2026 and top-line results in early 2027. The company secured up to $175 million in financing ensuring cash runway through 2027, accelerating development of a subc…